Eyenovia Croissance future

Future contrôle des critères 2/6

Eyenovia devrait augmenter ses bénéfices et ses revenus de 37.7% et de 64% par an respectivement, tandis que le BPA devrait croître de croître de 44.8% par an.

Informations clés

37.7%

Taux de croissance des bénéfices

44.8%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices	23.7%
Taux de croissance des recettes	64.0%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	18 Nov 2024

Mises à jour récentes de la croissance future

Recent updates

Prévisions de croissance des bénéfices et des revenus

NasdaqCM:EYEN - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	17	-26	-24	N/A	1
12/31/2025	5	-26	-30	N/A	3
12/31/2024	1	-37	-36	N/A	3
9/30/2024	0	-38	-31	-30	N/A
6/30/2024	0	-37	-32	-30	N/A
3/31/2024	0	-32	-30	-27	N/A
12/31/2023	0	-27	-28	-24	N/A
9/30/2023	0	-25	-27	-23	N/A
6/30/2023	N/A	-25	-26	-24	N/A
3/31/2023	N/A	-26	-25	-24	N/A
12/31/2022	N/A	-28	-26	-25	N/A
9/30/2022	10	-19	-27	-26	N/A
6/30/2022	10	-17	-25	-24	N/A
3/31/2022	12	-15	-26	-24	N/A
12/31/2021	14	-13	-22	-21	N/A
9/30/2021	6	-20	-11	-10	N/A
6/30/2021	6	-19	-7	-6	N/A
3/31/2021	4	-20	-6	-5	N/A
12/31/2020	2	-20	-7	-6	N/A
9/30/2020	N/A	-21	-16	-16	N/A
6/30/2020	N/A	-20	-18	-18	N/A
3/31/2020	N/A	-21	-19	-19	N/A
12/31/2019	N/A	-21	-19	-19	N/A
9/30/2019	N/A	-22	-19	-19	N/A
6/30/2019	N/A	-22	-19	-19	N/A
3/31/2019	N/A	-20	-17	-17	N/A
12/31/2018	N/A	-17	-13	-13	N/A
9/30/2018	N/A	-13	-11	-11	N/A
6/30/2018	N/A	-10	N/A	-8	N/A
3/31/2018	N/A	-7	N/A	-6	N/A
12/31/2017	N/A	-5	N/A	-5	N/A
9/30/2017	N/A	-4	N/A	-4	N/A
12/31/2016	N/A	-4	N/A	-3	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: EYEN devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: EYEN devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: EYEN devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de EYEN ( 64% par an) devrait croître plus rapidement que le marché US ( 8.9% par an).

Croissance élevée des revenus: Le chiffre d'affaires de EYEN ( 64% par an) devrait croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de EYEN devrait être élevé dans 3 ans

Eyenovia Croissance future

Future contrôle des critères 2/6

Informations clés

Mises à jour récentes de la croissance future

Consensus revenue estimates decrease by 47%

Price target decreased by 11% to US$8.33

Consensus revenue estimates decrease by 32%, EPS upgraded

Consensus revenue estimates increase by 40%

Consensus revenue estimates increase by 27%

Consensus revenue estimates increase by 32%

Recent updates

Eyenovia, Inc. has filed a Follow-on Equity Offering in the amount of $1.3 million.

New minor risk - Profitability

New major risk - Market cap size

Eyenovia, Inc. Provides Update on Phase 3 CHAPERONE Study

Eyenovia, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Eyenovia, Inc. Announces Presentation of Phase 3 Clobetasol Study Results at the American Academy of Ophthalmology (AAO) 2024 Expo

Eyenovia, Inc. has filed a Follow-on Equity Offering in the amount of $25 million.

Eyenovia, Inc. has filed a Follow-on Equity Offering in the amount of $4 million.

Eyenovia, Inc. Receives A Letter from the Staff of the Nasdaq Stock Market Regarding Bid Price Requirement

Eyenovia, Inc. Announces Chief Financial Officer Changes

Eyenovia, Inc. has completed a Follow-on Equity Offering in the amount of $5.14 million.

Eyenovia, Inc. has filed a Follow-on Equity Offering.

New major risk - Financial position

Consensus revenue estimates decrease by 47%

Price target decreased by 11% to US$8.33

Eyenovia, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Eyenovia Receives Letter from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2)

New major risk - Shareholder dilution

Consensus revenue estimates decrease by 32%, EPS upgraded

Eyenovia, Inc. to Report Q1, 2024 Results on May 15, 2024

Eyenovia, Inc., Annual General Meeting, Jun 12, 2024

Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi and Clobetasol Propionate Ophthalmic Suspension

New major risk - Share price stability

Eyenovia, Inc. has filed a Follow-on Equity Offering in the amount of $2 million.

Consensus revenue estimates increase by 40%

Consensus revenue estimates increase by 27%

Consensus revenue estimates increase by 32%

Eyenovia, Inc. to Report Q4, 2023 Results on Mar 18, 2024

Price target decreased by 8.6% to US$10.67

Consensus revenue estimates increase by 33%

Consensus revenue estimates increase by 33%

Is Eyenovia (NASDAQ:EYEN) Weighed On By Its Debt Load?

Consensus revenue estimates increase by 54%

New minor risk - Share price stability

High number of new directors

Eyenovia, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Eyenovia, Inc. Announces Fda Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production

Is Eyenovia (NASDAQ:EYEN) Using Debt In A Risky Way?

Eyenovia, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Is Eyenovia (NASDAQ:EYEN) Using Debt Sensibly?

Insider recently bought US$234k worth of stock

Eyenovia, Inc., Annual General Meeting, Jun 27, 2023

Eyenovia, Inc. Announces FDA Approval of Mydcombi, the First Ophthalmic Spray for Mydriasis

Eyenovia, Inc. to Report Q1, 2023 Results on May 11, 2023

Co-Founder recently sold US$300k worth of stock

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

No longer forecast to breakeven

No longer forecast to breakeven

Eyenovia, Inc. Showcases Microdose Array Print (MAP™) Technology At CES 2023 in Las Vegas

Eyenovia, Inc. Announces Positive Results from a Research Study

Forecast to breakeven in 2025

High number of new directors

Eyenovia Aims to Revolutionize Ophthalmology Devices with Microdose Array Print (Map) Technology

Eyenovia, Inc. Announces U.S. Food and Drug Administration Acceptance of New Drug Application for MydCombi™ for In-Office Pupil Dilation

Eyenovia, Inc. Announces Promotion of Bren Kern to Chief Operating Officer and Corporate Vice President, Effective January 1, 2023 and Julia Haller Steps Down from its Board of Directors

Price target decreased to US$14.33

Third quarter 2022 earnings released: US$0.21 loss per share (vs US$0.21 loss in 3Q 2021)

Third quarter 2022 earnings released: US$0.21 loss per share (vs US$0.21 loss in 3Q 2021)

Eyenovia, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Does Eyenovia (NASDAQ:EYEN) Have A Healthy Balance Sheet?

Eyenovia, Inc Announces Positive Results from VISION-2 Phase 3 Study of MicroLine as a Potential On-Demand Treatment for Presbyopia

Eyenovia gains as H.C. Wainwright initiates with Buy on pipeline potential

Eyenovia, Inc. Announces Retirement of Ken Lee as Lead Independent Director

Eyenovia's Novel Optejet® Dispenser Puts People's Eyes First

First half 2022 earnings released

Eyenovia, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Eyenovia, Inc. Announces Board Changes